Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q3 2019 · 10-Q
Revenue$3.60B$3.60B+4.7% vs Q3 2018 Net Income$1.55B$1.55B+7.0% vs Q3 2018 EPS Diluted$8.39$8.39+17.3% vs Q3 2018 Gross Profit$3,170,100,000+6.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,694,900,000−2.4% Free Cash Flowderived$1,604,800,000+2.0% Margins · derivedGross margin88.1%+1.5 pt vs Q3 2018
Operating margin50.2%+0.8 pt vs Q3 2018
Net margin42.9%+0.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 22, 2019 · 22 d after period end